<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004937</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16991G</org_study_id>
    <secondary_id>EORTC-16991G</secondary_id>
    <secondary_id>XENOVA-XR5000/014/98</secondary_id>
    <nct_id>NCT00004937</nct_id>
  </id_info>
  <brief_title>Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Patients With Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating&#xD;
      patients who have recurrent glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy acridine carboxzmide in terms of objective response&#xD;
      rate and response duration in patients with glioblastoma multiforme. II. Determine the&#xD;
      toxicities of this treatment regimen in this patient population.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients receive acridine carboxamide IV continuously&#xD;
      over days 1-5. Treatment repeats every 3 weeks for at least 2 courses and up to a maximum of&#xD;
      6 courses in the absence of disease progression or unacceptable toxicity. Patients are&#xD;
      followed every 6 weeks until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <primary_completion_date type="Actual">May 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acridine carboxamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed recurrent glioblastoma&#xD;
        multiforme Measurable disease on contrast MRI Lesion at least 2 cm in diameter&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Karnofsky 70-100%&#xD;
        Life expectancy: At least 3 months Hematopoietic: WBC greater than 3,000/mm3 Platelet count&#xD;
        greater than 100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
        Alkaline phosphatase no greater than 2 times ULN Transaminases no greater than 2 times ULN&#xD;
        Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: Normal cardiac function No&#xD;
        ischemic heart disease within the past 6 months Normal electrocardiogram Other: No unstable&#xD;
        systemic diseases No active uncontrolled infections No prior or other concurrent&#xD;
        malignancies except adequately treated basal or squamous cell skin cancer or carcinoma in&#xD;
        situ of the cervix No psychological, familial, sociological, or geographical condition that&#xD;
        would preclude study Not pregnant or nursing Fertile patients must use effective&#xD;
        contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks&#xD;
        since prior adjuvant chemotherapy for brain tumor No other prior chemotherapy Endocrine&#xD;
        therapy: Must be on stable or decreasing doses of corticosteroids for at least 2 weeks&#xD;
        Radiotherapy: At least 3 months since prior radiotherapy to the brain No prior high dose&#xD;
        radiotherapy No prior stereotactic boost or implant radiotherapy Surgery: No prior surgery&#xD;
        (except biopsy) for recurrent brain tumor At least 3 months since prior surgery for primary&#xD;
        brain tumor Other: No other concurrent anticancer agents No other concurrent&#xD;
        investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Twelves, MD, BMedSci, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>August 6, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2004</study_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

